微創醫療(00853.HK)斥1.11億人幣收購活性藥物成分業務45%股權
微創醫療(00853.HK)公佈,附屬上海微創與福建省六一八產業股權投資合夥企業,和作爲轉讓人的福建省招標採購集團簽署股權轉讓合同,上海微創將作爲戰略投資人,以1.11億元人民幣收購轉讓人持有的科瑞藥業45%的股權。完成後,上海微創將成爲科瑞藥業單一最大股東,上海微創並將通過協議安排獲得科瑞藥業日常經營的控制權。
科瑞藥業從事免疫抑制劑和抗腫瘤藥等高附加值的發酵型活性藥物成分(活性藥物成分)的研發、生產及銷售的國家高新技術企業,持有中國國家藥品監督管理局、美國食品藥品監督管理局和歐盟CE的GMP認證及註冊證。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.